Alpha-1 antitrypsin deficiency

Alpha-1 antitrypsin deficiency (AATD) is a rare hereditary condition caused by decreased plasma and tissue levels of alpha-1 antitrypsin (AAT) that can lead to serious lung and liver disease in children and adults. AATD patients face challenges such as under diagnosis, clinical variability, and limited treatment options for liver disease. Early detection and biomarkers for predicting outcomes are needed to improve patient outcome. Currently, the only approved pharmacological therapy is augmentation therapy, which can delay the progression of emphysema. However, alternative strategies such as gene therapy, induced pluripotent stem cells, and prevention of AAT polymerization inside hepatocytes are being investigated. This review aims to summarize and update current knowledge on AATD, identify areas of controversy, and formulate questions for further research. (AU)

El déficit de alfa-1 antitripsina (DAAT) es una enfermedad hereditaria poco frecuente causada por la disminución de los niveles plasmáticos y tisulares de alfa-1 antitripsina (AAT) que puede provocar enfermedades pulmonares y hepáticas graves en niños y adultos. Aquellos con DAAT se enfrentan a retos como el infradiagnóstico, la variabilidad clínica y a las limitadas opciones de tratamiento para la enfermedad hepática. La detección precoz y los biomarcadores para predecir los resultados clínicos son necesarios para mejorar la evolución de los pacientes. En la actualidad, el único tratamiento farmacológico aprobado es la terapia de reposición, que puede retrasar la progresión del enfisema. Sin embargo, se están investigando estrategias alternativas como la terapia génica, las células madre pluripotentes inducidas y la prevención de la polimerización de la AAT en el interior de los hepatocitos. Esta revisión pretende resumir y actualizar los conocimientos actuales sobre la AATD, identificar las áreas de controversia y formular preguntas para futuras investigaciones. (AU)

[Assessment of blood eosinophil count in respiratory disease from primary care]. / Valoración del recuento sanguíneo de eosinófilos en la patología respiratoria desde atención primaria.

Most physicians in general, and family physicians in particular, are familiar with certain parameters when ordering a hematological study, such as hemoglobin (including hematocrit and its features), leukocytes (including lymphocytes) and platelets. Nevertheless, there are two values that we use to overlook which are eosinophils and basophils. Specifically, eosinophils have a tendency to increase with allergic pathology. This article focuses on this type of cells, helping to interpret the values obtained and highlighting their importance in two of the most frequent respiratory pathologies in primary care: asthma and COPD. In addition to observing how the increase or normality of these parameters condition the diagnosis, phenotype and even the treatment.

Oxygen uptake during the last bouts of exercise incorporated into high-intensity intermittent cross-exercise exceeds the V˙ O2max of the same exercise mode.

Oxygen uptake (V˙ O2) was measured during a non-exhaustive high-intensity intermittent cross-exercise (HIICE) protocol consisting of four alternating bouts of 20 â€‹s running (R) and three bouts of bicycle exercise (BE) at ∼160% and ∼170% maximal oxygen uptake (V˙ O2max), respectively, with 10 â€‹s between-bout rests (sequence R-BE-R-BE-R-BE-R). The V˙ O2 during the last BE ([52.2 â€‹± â€‹5.0] mL·kg-1·min-1) was significantly higher than the V˙ O2max of the BE ([48.0 â€‹± â€‹5.4] mL·kg-1·min-1, n â€‹= â€‹30) and similar to that of running. For clarifying the underlying mechanisms, a corresponding HIICE-protocol with BE and arm cranking ergometer exercise (AC) was used (sequence AC-AC-BE-AC-BE-AC-AC-BE). In some experiments, thigh blood flow was occluded by a cuff around the upper thigh. Without occlusion, the V˙ O2 during the AC ([39.2 â€‹± â€‹7.1] mL·kg-1·min-1 [6th bout]) was significantly higher than the V˙ O2max of AC ([30.2 â€‹± â€‹4.4] mL·kg-1·min-1, n â€‹= â€‹7). With occlusion, the corresponding V˙ O2 ([29.8 â€‹± â€‹3.9] mL·kg-1·min-1) was reduced to that of the V˙ O2max of AC and significantly less than the V˙ O2 without occlusion. These findings suggest that during the last bouts of HIICE may exceed the of the specific exercise, probably because it is a summation of the V˙ O2 for the ongoing exercise plus excess post-oxygen consumption (EPOC) produced by the previous exercise with a higher V˙ O2max.

Impacto pronóstico de la enfermedad pulmonar obstructiva crónica y el asma bronquial en pacientes con insuficiencia cardiaca / Prognostic impact of chronic obstructive pulmonary disease and bronchial asthma in patients with heart failure

Propósito Analizar el impacto de la enfermedad pulmonar obstructiva crónica (EPOC) y el asma bronquial sobre el manejo terapéutico y el pronóstico de los pacientes con insuficiencia cardiaca (IC). Métodos Análisis de la información contenida en un registro clínico de pacientes remitidos a una unidad especializada de IC entre enero de 2010 y junio de 2022. Se compararon su perfil clínico, el tratamiento y el pronóstico en base a la presencia de EPOC o asma bronquial. El análisis de supervivencia se realizó mediante los métodos de Kaplan-Meier y Cox. La mediana de seguimiento fue de 1.493 días. Resultados Se estudiaron 2.577 pacientes, de los cuales 251 (9,7%) presentaban EPOC y 96 (3,7%), asma bronquial. Observamos diferencias significativas entre los tres grupos con respecto a la prescripción de betabloqueantes (EPOC=89,6%; asma=87,5%; no broncopatía=94,1%; p=0,002) e inhibidores del cotransportador de sodio-glucosa tipo2 (EPOC=35,1%; asma=50%; no broncopatía=38,3%; p=0,036). Además, los pacientes con patología bronquial recibieron con menor frecuencia un desfibrilador (EPOC=20,3%; asma=20,8%; no broncopatía=29%; p=0,004). La presencia de EPOC se asoció de forma independiente con mayor riesgo de muerte por cualquier causa (HR=1,64; IC95%: 1,33-2,02), muerte u hospitalización por IC (HR=1,47; IC95%: 1,22-1,76) y muerte cardiovascular o trasplante cardiaco (HR=1,39; IC95%: 1,08-1,79) en comparación con la ausencia de broncopatía. La presencia de asma bronquial no se asoció a un impacto significativo sobre los desenlaces analizados. Conclusiones La EPOC, pero no el asma bronquial, es un factor pronóstico adverso e independiente en pacientes con IC. (AU)

Purpose To analyze the impact of chronic obstructive pulmonary disease (COPD) and bronchial asthma on therapeutic management and prognosis of patients with heart failure (HF). Methods Analysis of the information collected in a clinical registry of patients referred to a specialized HF unit from January-2010 to June-2012. Clinical profile, treatment and prognosis of patients was evaluated, according to the presence of COPD or asthma. Survival analyses were conducted by means of Kaplan-Meier and Cox's methods. Median follow-up was 1493 days. Results We studied 2577 patients, of which 251 (9.7%) presented COPD and 96 (3.7%) bronchial asthma. Significant differences among study groups were observed regarding to the prescription of beta-blockers (COPD=89.6%; asthma=87.5%; no bronchopathy=94.1%; P=.002) and SGLT2 inhibitors (COPD=35.1%; asthma=50%; no bronchopathy=38.3%; P=.036). Also, patients with bronchial disease received less frequently a defibrillator (COPD=20.3%; asthma=20.8%; no broncopathy=29%; P=.004). COPD was independently associated with increased risk of all-cause mortality (HR=1.64; 95%CI: 1.33-2.02), all-cause death or HF admission (HR=1.47; 95%CI: 1.22-1.76) and cardiovascular death or heart transplantation (HR=1.39; 95%CI: 1.08-1.79) as compared with patients with no bronchopathy. Bronchial asthma was not significantly associated with increased risk of adverse outcomes. Conclusions COPD, but not asthma, is an adverse independent prognostic factor in patients with HF. (AU)

Prognostic impact of chronic obstructive pulmonary disease and bronchial asthma in patients with heart failure.

PURPOSE: To analyze the impact of chronic obstructive pulmonary disease (COPD) and bronchial asthma on therapeutic management and prognosis of patients with heart failure (HF). METHODS: Analysis of the information collected in a clinical registry of patients referred to a specialized HF unit from January-2010 to June-2012. Clinical profile, treatment and prognosis of patients was evaluated, according to the presence of COPD or asthma. Survival analyses were conducted by means of Kaplan-Meier and Cox's methods. Median follow-up was 1493 days. RESULTS: We studied 2577 patients, of which 251 (9.7%) presented COPD and 96 (3.7%) bronchial asthma. Significant differences among study groups were observed regarding to the prescription of beta-blockers (COPD=89.6%; asthma=87.5%; no bronchopathy=94.1%; p=0.002) and SGLT2 inhibitors (COPD=35.1%; asthma=50%; no bronchopathy=38.3%; p=0.036). Also, patients with bronchial disease received less frequently a defibrillator (COPD=20.3%; asthma=20.8%; no broncopathy=29%; p=0.004). COPD was independently associated with increased risk of all-cause mortality (HR=1.64; 95% CI 1.33-2.02), all-cause death or HF admission (HR=1.47; 95% CI 1.22-1.76) and cardiovascular death or heart transplantation (HR=1.39; 95% CI 1.08-1.79) as compared with patients with no bronchopathy. Bronchial asthma was not significantly associated with increased risk of adverse outcomes. CONCLUSIONS: COPD, but not asthma, is an adverse independent prognostic factor in patients with HF.

EEG alpha and theta time-frequency structure during a written mathematical task.

Since the first electroencephalogram (EEG) was obtained, there have been many possibilities to use it as a tool to access brain cognitive dynamics. Mathematical (Math) problem solving is one of the most important cortical processes, but it is still far from being well understood. EEG is an inexpensive and simple indirect measure of brain operation, but only recently has low-cost equipment (mobile EEG) allowed sophisticated analyses in non-clinical settings. The main purpose of this work is to study EEG activation during a Math task in a realistic environment, using mobile EEG. A matching pursuit (MP)-based signal analysis technique was employed, since MP properties render it a priori suitable to study induced EEG activity over long time sequences, when it is not tightly locked to a given stimulus. The study sample comprised sixty healthy volunteers. Unlike the majority of previous studies, subjects were studied in a sitting position with their eyes open. They completed a written Math task outside the EEG lab, wearing a mobile EEG device (EPOC+). Theta [4 Hz-7.5 Hz], alpha (7.5 Hz-13 Hz] and 0.5 Hz micro-bands in the [0.5 Hz-20 Hz] range were studied with a low-density stochastic MP dictionary. Over 1-min windows, ongoing EEG alpha and theta activity was decomposed into numerous MP atoms with median duration around 3 s, similar to the duration of induced, time-locked activity obtained with event-related (des)synchronization (ERS/ERD) studies. Relative to Rest, there was lower right-side and posterior MP alpha atom/min during Math, whereas MP theta atom/min was significantly higher on anteriorly located electrodes, especially on the left side. MP alpha findings were particularly significant on a narrow range around 10 Hz-10.5 Hz, consistent with FFT alpha peak findings from ERS/ERD studies. With a streamlined protocol, these results replicate previous findings of EEG alpha and theta activation obtained during Math tasks with different signal analysis techniques and in different time frames. The efficient application to real-world, noisy EEG data with a low-resolution stochastic MP dictionary shows that this technique is very encouraging. These results provide support for studies of mathematical cognition with mobile EEG and matching pursuit.

Chronic obstructive pulmonary disease mortality in Spain between 1999 and 2019 / Mortalidad por enfermedad pulmonar obstructiva crónica en España entre 1999 y 2019

Introduction Mortality from COPD has decreased in Spain in recent years, but it is unknown whether this decline has been homogeneous among the different regions. Methods From the Statistical Portal of the Ministry of Health of Spain we obtained the age-adjusted mortality rates/100,000 inhabitants for men and women in Spain and the Autonomous Communities for the years 1999–2019, using the coding of the International Classification of Diseases (ICD 10, sections J40–J44). With the adjusted rates we performed a jointpoint regression analysis to estimate an annual percentage change (APC), as well as identify possible points of trend change. Statistical significance was considered for a value of p<0.05. Results During the study period, COPD mortality rates adjusted in Spain decreased from 28.77 deaths/100,000 inhabitants in 1999 to 12.14 deaths/100,000 inhabitants in 2019. We observed a linear decline in COPD mortality in men at national level of −3.67% per year (95% CI −4.1 to −3.4; p<0.001), with differences between the Autonomous Communities. Mortality in women also experienced a decrease in mortality in two phases, with a first period from 1999 to 2006 with a fall of −6.8% per year (95% CI −8.6 to −5.0; p<0.001) and a second period from 2006 to 2019 with a decrease in mortality of −2.1% (95% CI −2.8 to −1.3; p<0.001), with again differences between the Autonomous Communities. Conclusion Mortality rates from COPD have decreased heterogeneously among the different Autonomous Communities in both men and women (AU)

Introducción La mortalidad por EPOC ha disminuido en España en los últimos años, pero se desconoce si esta caída ha sido homogénea entre las diferentes comunidades autónomas. Metodología consultando el Portal Estadístico del Ministerio de Sanidad de España obtuvimos las tasas ajustadas por edad/100.000 habitantes para hombres y mujeres de España y las CCAA para los años 1999 a 2019, utilizando la codificación de la Clasificación Internacional de Enfermedades (CIE 10, secciones J40 a J44). Con las tasas ajustadas realizamos un análisis de regresión de jointpoint con el objetivo de estimar un porcentaje anual de cambio (APC), así como identificar posibles puntos de cambio de tendencia. Se consideró la significación estadística para un valor de p<0.05. Resultados Durante el periodo de estudio, las tasas de mortalidad global ajustada por EPOC en España pasaron de 28.77 muertes/100.000 habitantes en 1999 a 12.14 muertes/100.000 habitantes en 2019. Observamos una caída de la mortalidad por EPOC en varones a nivel de España lineal del -3.67% anual (IC 95% -4.1 a -3.4; p<0.001), con diferencias entre las CCAA. La mortalidad en mujeres también experimentó una disminución de mortalidad en dos fases, con un primer periodo de 1999 a 2006 con caída del -6.8% anual (IC 95% -8.6 a -5.0; p<0.001) y un segundo periodo de 2006 a 2019 con un descenso de la mortalidad del -2.1% (IC 95% -2.8 a -1.3; p<0.001), encontrando diferencias entre las CCAA. Conclusiones Las tasas de mortalidad por EPOC han disminuido de forma heterogénea entre las diferentes CCAA (AU)

Excess post-exercise oxygen consumption after reduced exertion high-intensity interval training on the cycle ergometer and rowing ergometer.

PURPOSE: To examine differences in oxygen consumption ([Formula: see text]O2), ventilation ([Formula: see text]E), excess post-exercise oxygen consumption (EPOC), energy expenditure (EE), and blood lactate concentration (BLa) between reduced exertion high-intensity interval training (REHIT) performed on the cycle- and rowing ergometer. METHODS: Fourteen active participants (age = 27 ± 7 yr) initially completed two assessments of maximal oxygen uptake. On two subsequent days, participants completed REHIT requiring three 20 s "all-out" sprints on the cycle-(REHIT-CE) and rowing ergometer (REHIT-RE), followed by 60 min rest during which gas exchange data and BLa were measured. RESULTS: During exercise, [Formula: see text]O2 increased significantly in response to REHIT-CE (0.21 ± 0.04 L/min vs. 1.34 ± 0.37 L/min, p < 0.001) and REHIT-RE (0.23 ± 0.05 L/min vs. 1.57 ± 0.47 L/min, p < 0.001) compared to rest, and [Formula: see text]O2 remained elevated at 15, 30, and 45 min post-exercise in REHIT-CE (p < 0.001). However, [Formula: see text]O2 was only elevated 15 min after REHIT-RE (0.23 ± 0.05 L/min vs. 0.40 ± 0.11 L/min, p < 0.001). [Formula: see text]O2 (1.57 ± 0.47 L/min vs. 1.34 ± 0.37 L/min, p = 0.003) and EE (94.98 ± 29.60 kcal vs. 82.05 ± 22.85 kcal, p < 0.001) were significantly greater during REHIT-RE versus REHIT-CE. EPOC was significantly greater after REHIT-CE versus REHIT-RE (6.69 ± 2.18 L vs. 5.52 ± 1.67 L, p = 0.009). BLa was ~ twofold higher in response to REHIT-CE vs. REHIT-RE (11.11 ± 2.43 vs. 7.0 ± 2.4, p < 0.001). CONCLUSION: Rowing-based REHIT elicits greater oxygen consumption and EE during exercise, yet lower EPOC and BLa. Whether rowing-based REHIT augments reductions in fat loss remains to be determined.

Alpha-1 antitrypsin deficiency.

Alpha-1 antitrypsin deficiency (AATD) is a rare hereditary condition caused by decreased plasma and tissue levels of alpha-1 antitrypsin (AAT) that can lead to serious lung and liver disease in children and adults. AATD patients face challenges such as under diagnosis, clinical variability, and limited treatment options for liver disease. Early detection and biomarkers for predicting outcomes are needed to improve patient outcome. Currently, the only approved pharmacological therapy is augmentation therapy, which can delay the progression of emphysema. However, alternative strategies such as gene therapy, induced pluripotent stem cells, and prevention of AAT polymerization inside hepatocytes are being investigated. This review aims to summarize and update current knowledge on AATD, identify areas of controversy, and formulate questions for further research.

Chronic obstructive pulmonary disease mortality in Spain between 1999 and 2019.

INTRODUCTION: Mortality from COPD has decreased in Spain in recent years, but it is unknown whether this decline has been homogeneous among the different regions. METHODS: From the Statistical Portal of the Ministry of Health of Spain we obtained the age-adjusted mortality rates/100,000 inhabitants for men and women in Spain and the Autonomous Communities for the years 1999-2019, using the coding of the International Classification of Diseases (ICD 10, sections J40-J44). With the adjusted rates we performed a jointpoint regression analysis to estimate an annual percentage change (APC), as well as identify possible points of trend change. Statistical significance was considered for a value of p<0.05. RESULTS: During the study period, COPD mortality rates adjusted in Spain decreased from 28.77 deaths/100,000 inhabitants in 1999 to 12.14 deaths/100,000 inhabitants in 2019. We observed a linear decline in COPD mortality in men at national level of -3.67% per year (95% CI -4.1 to -3.4; p<0.001), with differences between the Autonomous Communities. Mortality in women also experienced a decrease in mortality in two phases, with a first period from 1999 to 2006 with a fall of -6.8% per year (95% CI -8.6 to -5.0; p<0.001) and a second period from 2006 to 2019 with a decrease in mortality of -2.1% (95% CI -2.8 to -1.3; p<0.001), with again differences between the Autonomous Communities. CONCLUSION: Mortality rates from COPD have decreased heterogeneously among the different Autonomous Communities in both men and women.

Eficacia de la telerrehabilitación en pacientes con enfermedad pulmonar obstructiva crónica: revisión sistemática / Efficacy of tele-rehabilitation in patients with chronic obstructive pulmonary disease: A systematic review

Desde 2020 se ha vivido una situación sin precedentes, experimentando un confinamiento total de la población debido al SARS-CoV-2, que ha afectado al tratamiento de distintas patologías, como la enfermedad pulmonar obstructiva crónica (EPOC). Por ello, se implementaron programas de telerrehabilitación para continuar los tratamientos. Se realizó una búsqueda bibliográfica entre octubre y noviembre de 2020, cuyo objetivo fue analizar y actualizar la eficacia de la telerrehabilitación en pacientes con EPOC, y 8 artículos cumplieron los criterios de selección. La telerrehabilitación pulmonar reflejó mejoras en la calidad de vida y estado físico, y disminuyó las hospitalizaciones y exacerbaciones. Asimismo, los pacientes mostraron un grado elevado de satisfacción y adherencia. La telerrehabilitación pulmonar obtiene resultados similares a la rehabilitación pulmonar, pudiendo utilizarla en pacientes con dificultad de desplazamiento a su centro sanitario o en confinamiento. No obstante, se debe investigar qué programa de telerrehabilitación es el ideal.(AU)

Since 2020 we have lived an exceptional situation that made us experience a complete lockdown due to SARS-CoV-2, what affected the treatments of different pathologies, such as the chronic obstructive pulmonary disease (COPD). Because of those reasons, it has arisen the idea of implementing the tele-rehabilitation program as a treatment of these pathologies. The search was done between the months of October and November 2020, with the aim of analyzing and updating the efficacy of the tele-rehabilitation in patients who have COPD, finding eight articles which met the inclusion criteria. The pulmonary tele-rehabilitation is able to improve the quality of life and physical state, and decreasing the number of hospitalizations and exacerbations. Furthermore, patients showed a great level of satisfaction and adherence to this treatment program. The pulmonary tele-rehabilitation can achieve similar results as of pulmonary rehabilitation. For this reason, people who have difficulties to go to their outpatients clinic or even in a lockdown can use it. However, it is necessary to investigate which tele-rehabilitation program is better.(AU)

Inercia clínica o terapéutica en neumología: una reflexión sobre su definición y actores principales / Clinical or therapeutic inertia in pneumology: critical reflection on its definition and main actors

La inercia clínica se define como los fallos del médico en el inicio o la intensificación del tratamiento cuando están indicados. Nuestro objetivo es reflexionar sobre este concepto aplicado en enfermedad pulmonar obstructiva crónica y asma, y el papel del profesional sanitario y del sistema de salud como actores implicados. Dejamos aparte la inercia del paciente para otro ámbito de estudio e intervención. Proponemos definir la inercia clínica para procesos durante el diagnóstico y el tratamiento cuando no se inicia o modifica (intensifica o disminuye) una terapia. También se identifican los factores que contribuyen a la inercia clínica o terapéutica y se plantean estrategias de mejora. (AU)

Clinical inertia is defined as the physician’s failure to initiate or intensify treatment when it is indicated. Our objective is to reflect on this concept applied to chronic obstructive pulmonary disease and asthma, and the role of health professional and health system as stakeholders. We leave patient inertia aside for another area of study and intervention. We propose to define clinical inertia for diagnosis and therapeutic processes when a treatment is not started or modified (intensifies or decreases). Factors that contribute to clinical and/or therapeutic inertia are also identified and improvement strategies are proposed. (AU)

Crowdsourced EEG experiments: A proof of concept for remote EEG acquisition using EmotivPRO Builder and EmotivLABS.

The development of online research platforms has made data collection more efficient and representative of populations. However, these benefits have not been available for use with cognitive neuroscience tools such as electroencephalography (EEG). In this study, we introduce an approach for remote EEG data collection. We demonstrate how an experiment can be built via the EmotivPRO Builder and deployed to the EmotivLABS website where it can be completed by participants who own EMOTIV EEG headsets. To demonstrate the data collection technique, we collected EEG while participants engaged in a resting state task where participants sat with their eyes open and then eyes closed for 2 min each. We observed a significant difference in alpha power between the two conditions thereby demonstrating the well-known alpha suppression effect. Thus, we demonstrate that EEG data collection, particularly for frequency domain analysis, can be successfully conducted online.

Electrochemical Promotion of CO2 Hydrogenation Using a Pt/YSZ Fuel Cell Type Reactor.

The hydrogenation of CO2 is a reaction of key technological and environmental importance, as it contributes to the sustainable production of fuels while assisting in the reduction of a major greenhouse gas. The reaction has received substantial attention over the years within the catalysis and electrocatalysis communities. In this respect, the electrochemical promotion of catalysis (EPOC) has been applied successfully to the CO2 hydrogenation reaction to improve the catalytic activity and selectivity of conductive films supported on solid electrolytes. However, designing an effective electrocatalytic reactor remains a challenge due to the connections required between the electrodes and the external potentiostat/galvanostat. This drawback could be alleviated if the catalytic reaction occurs in a reactor that simultaneously operates as a power generator. In this work, the Electrochemical Promotion of the CO2 hydrogenation reaction in a low-temperature solid oxide electrolyte fuel cell (SOFC) reactor is studied using yttria-stabilized zirconia (YSZ) and a platinum (Pt) electrode catalyst. The system has been studied in two distinct operation modes: (i) when the necessary energy for the electrochemical promotion is produced through the parallel reaction of H2 oxidation (galvanic operation) and (ii) when a galvanostat/potentiostat is used to impose the necessary potential (electrolytic operation). The performance of the fuel cell declines less than 15% in the presence of the reactant mixture (CO2 and H2) while producing enough current to conduct EPOC experiments. During the electrolytic operation of the electrochemical cell, the CO production rate is significantly increased by up to 50%.

Participación social en adultos mayores con Enfermedad Pulmonar Obstructiva Crónica: características funcionales y emocionales / Social participation in older adults with Chronic Obstructive Pulmonary Disease: functional and emotional characteristics

Fundamentos: El impacto de la enfermedad pulmonar obstructiva crónica (EPOC) sobre la participación social en actividadesde la comunidad ha sido poco estudiada en adultos mayores. Por esta razón, este estudio analizó los tipos de organizaciones comunitarias donde participan los adultos mayores con EPOC y sus características funcionales y emocionales.Métodos: Fue realizado un estudio transversal con treinta y nueve adultos mayores con EPOC, de la ciudad de Londrina (Brasil),desde el año 2016 hasta 2019. Fue aplicado el cuestionario de participación social para conocer la participación en reuniones oactividades con: 1) organizaciones de adultos mayores; 2) junta de vecinos o partido político; 3) grupos religiosos, de crecimientopersonal o espiritual; 4) actividades familiares o con amigos; y 5) actividades recreativas en la comunidad. Los individuos realizaronel test de marcha de seis minutos (TM6m), Inventario de Depresión de Beck (IDB), evaluación de fuerza de prensión palmar (FPP) y elCOPD Assessment Test (CAT). La comparación entre los adultos mayores que participaron de organizaciones formales e informalesfue realizada utilizando el Test T de Student.Resultados: El 77% de los pacientes con EPOC participaron en grupos religiosos o espirituales y el 74% en actividades con familiares y amigos. Las mujeres participaron más en actividades sociales informales (P=0,002) y formales (P=0,004) que los hombres.Individuos que participaron en actividades sociales son aquellos que tuvieron menor rendimiento en TM6m y mayores puntuacionesen IDB y CAT (P<0,05 para todos).Conclusiones: La participación social de los adultos mayores con EPOC es mayor en grupos religiosos, actividades familiaresy con amigos. Adicionalmente, los adultos mayores que participan en organizaciones comunitarias son aquellos que presentan máslimitaciones funcionales y emocionales...(AU)

Backgroud: The impact of chronic obstructive pulmonary disease (COPD) on social participation in community activities hasbeen scarce studied in older adults. For this reason, this study analyzed the types of community organizations in which older adultswith COPD participate and their functional and emotional characteristics. Methods: A cross-sectional study was conducted with 39 older adults with COPD from the city of Londrina (Brazil), from 2016 to2019. The social participation questionnaire was applied to identify the participation in meetings or activities with: 1) organizations forolder adults; 2) neighbourhood councils or political parties; 3) religious, personal or spiritual growth; 4) family or friends activities; 5)recreational activities in the community. The individuals performed the 6-minute walk test (6MWT), Beck Depression Inventory (BDI), han-dgrip strength (HGS), and the COPD Assessment Test (CAT). The comparison between older adults who participate in formal and informalorganizations was made using the Student’s T-Test. Results: 77% of COPD patients participated in religious or spiritual groups and 74% in activities with family and friends. Womenparticipated more in informal (P=0.002) and formal (P=0.004) social activities than men. Individuals who have participated in socialactivities were those who had lower performance in 6MWT and higher scores in BDI and CAT (P<0.05 for all). Conclusions: The social participation of older adults with COPD is greater in religious groups, family activities and with friends.Additionally, older adults who participate in community organizations are those who have more functional and emotional limitations.This reinforces the role of community groups to support older adults with COPD who have some health limitation.(AU)

Corticoides inhalados como factor de riesgo de neumonía adquirida en la comunidad en enfermedad pulmonar obstructiva crónica

Objetivo: Determinar si el uso de corticoides inhalados es factor de riesgo de neumonía adquirida en la comunidad en pacientes con enfermedad pulmonar obstructiva crónica en el Hospital Víctor Lazarte Echegaray durante el período 2017-2020. Métodos: El estudio fue analítico, observacional, retrospectivo de casos y controles no emparejados a razón de 4:1, con una población de 405 sujetos; se seleccionaron 81 casos y 324 controles, quienes cumplieron los criterios de selección. Se realizó un muestro no probabilístico. Se incluyeron las variables, uso de corticoides inhalados, pacientes con neumonía adquirida en la comunidad, edad, sexo, desnutrición y tabaquismo. La medida de asociación se hizo utilizando la prueba no paramétrica Chi Cuadrado de Pearson y la prueba exacta de Fisher en frecuencias menores de 5. El análisis bivariado y multivariado se realizó mediante regresión logística múltiple con significancia estadística (valor p 0,05). Conclusión: El uso de corticoides inhalados no es factor de riesgo de neumonía adquirida en la comunidad en pacientes con enfermedad pulmonar obstructiva crónica.

Objective: To determine if the use of inhaled corticosteroids is a risk factor for community-acquired pneumonia in patients with Chronic Obstructive Pulmonary Disease at the Víctor Lazarte Echegaray Hospital during the period 2017-2020. Methods: The study was analytical, observational, retrospective of cases and unmatched controls in a ratio of 4:, with a population of 405 subjects from whom 81 cases and 324 controls were selected, who met the selection criteria. A non-probabilistic sampling was carried out. The variables, use of inhaled corticosteroids, patients with community-acquired pneumonia, age, sex, malnutrition and smoking were included. The association was measured using Pearson's non-parametric Chi-square test and Fisher's exact test at lower frequencies less than 5. The bivariate and multivariate analysis was performed using multiple logistic regression with statistical significance (p value 0.05). Conclusion: The use of inhaled corticosteroids is not a risk factor for community-acquired pneumonia in patients with chronic obstructive pulmonary disease.

[Efficacy of tele-rehabilitation in patients with chronic obstructive pulmonary disease: A systematic review]. / Eficacia de la telerrehabilitación en pacientes con enfermedad pulmonar obstructiva crónica: revisión sistemática.

Since 2020 we have lived an exceptional situation that made us experience a complete lockdown due to SARS-CoV-2, what affected the treatments of different pathologies, such as the chronic obstructive pulmonary disease (COPD). Because of those reasons, it has arisen the idea of implementing the tele-rehabilitation program as a treatment of these pathologies. The search was done between the months of October and November 2020, with the aim of analyzing and updating the efficacy of the tele-rehabilitation in patients who have COPD, finding eight articles which met the inclusion criteria. The pulmonary tele-rehabilitation is able to improve the quality of life and physical state, and decreasing the number of hospitalizations and exacerbations. Furthermore, patients showed a great level of satisfaction and adherence to this treatment program. The pulmonary tele-rehabilitation can achieve similar results as of pulmonary rehabilitation. For this reason, people who have difficulties to go to their outpatients clinic or even in a lockdown can use it. However, it is necessary to investigate which tele-rehabilitation program is better.

Relación entre la distancia recorrida en la prueba de caminata de 6 minutos y el sexo, la edad, comorbilidades y la disnea en pacientes con EPOC / Relationship between the Distance Traveled in the Test of 6- Minute Walk and Sex, Age, Comorbidities and Dyspnea in Patients with CORP

Introducción: la enfermedad pulmonar obstructiva crónica (EPOC) es un trastorno res-piratorio caracterizado por síntomas clínicos y compromiso funcional que afecta la ca-pacidad aeróbica limitando las actividades cotidianas y la calidad de vida. La prueba de caminata de 6 minutos (C6M) es una prueba sencilla y de bajo costo que evalúa la capa-cidad de los pacientes para realizar sus actividades cotidianas. Objetivo: evaluar la re-lación entre la capacidad aeróbica medida por la distancia recorrida en la C6M y el se-xo, edad, disnea y comorbilidades cardiometabólicas en pacientes con EPOC. Material y métodos: estudio de corte transversal, descriptivo, basado en pruebas de caminatas de 6 minutos (C6M) realizadas en pacientes con EPOC. Resultados: se evaluaron 101 pacientes, hombres (63,4%), con una edad promedio de 74,1±8,7 años. Al correlacionar C6M con otras variables se encontraron diferencias estadísticamente significativas. La distancia media recorrida fue mayor en hombres que en mujeres (DM: 58,3 metros, IC 95%; 16 - 100,6, p=0,007). Los pacientes < 75 años, sin comorbilidades y disnea < 2 tu-vieron mejor desempeño en la C6M que los > 75 años (DM; 62,012 metros IC 95% 21,5 - 102,4, p=0,003), con comorbilidades (DM: 42,2 metros, IC 95%, 0.003 - 84,4; p=0,050) y disnea ≥ 2 (DM: 65,8 IC 95% 23,9 - 107,6, p=0,002). Conclusiones: el sexo femenino, la presencia de comorbilidad cardiovascular y metabólica, y la edad se asocian con dis-minución en la capacidad física aeróbica y funcional en los pacientes con EPOC. (AU)

Introduction: chronic obstructive pulmonary disease (COPD) is a respiratory disorder characterized by clinical symptoms and functional impairment that affects aerobic capacity, limiting daily activities and quality of life. The 6-minute walk test (C6M) is a simple, low-cost test that assesses a patient's ability to perform their daily activities. Objective: to evaluate the relationship between aerobic capacity measured by the distance covered in the C6M and gender, age, dyspnea and cardiometabolic comorbidities in patients with COPD. Materials and methods: cross-sectional, descriptive study, based on 6-minute walk tests (C6M) performed in patients with COPD. Results: 101 male patients (63.4%), with a mean age of 74.1 ± 8.7 years, were evaluated. When correlating C6M with other variables, statistically significant differences were found. The mean distance traveled was greater in men than in women (MD: 58.3 meters, 95% CI: 16 - 100.6, p=0.007). Patients <75 years old, without comorbidities and dyspnea <2 had better performance in the C6M than those >75 years old (MD; 62 meters CI 95% 21.5 - 102.4, p=0.003), with comorbidities (MD: 42.2 meters, 95% CI, 0.003 - 84.4; p=0.050) and dyspnea ≥ 2 (MD: 65.8, 95% CI 23.9 - 107.6, p=0.002). Conclusions: female sex, the presence of cardiovascular and metabolic comorbidity, and age are associated with decreased aerobic and functional physical capacity in patients with COPD. (AU)

Female sexual dysfunction in chronic obstructive pulmonary disease

Background: Sexual life of women with chronic obstructive pulmonary disease (COPD) can be affected by breathing difficulties, a decrease in functional status, depressive mood and fatigue. Objetive: To evaluate the sexual dysfunction in female COPD patients and the possible explanatory mechanisms or correlations between these conditions. Methods: The study included 70 female patients with COPD aged between 36-65 and 70 age-matched controls. All the subjects completed questionnaires for the Female Sexual Functional Index (FSFI), BECK depression inventory and, spirometry. Results: Statistically significant sexual dysfunction was noted in COPD patients compared to the non-COPD group (p0.005). In linear regression analysis determining depression, no statistically significant factor was found among age, number of comorbidities, and FEV1/ forced vital capacity (FVC) % predicted (p>0.05). In multivariable analysis, only fatigue during intercourse was found to be a statistically significant factor in predicting sexual dysfunction among factors like age, presence of comorbidities, duration of the disease, smoking status, FEV1%, m MRCpoints, 6-minutes walk test, BECK depression scores (p=0.008). Conclusion: Sexual dysfunction is reported in many COPD females and seems to be related not to spirometric measures or exercise capacity but to fatigue. Depression is also a common comorbidity, of which both disorders are often neglected.

Antecedentes: La vida sexual en mujeres con enfermedad pulmonar obstructiva crónica (EPOC) es afectada por dificultades respiratorias, disminución del estado funcional, estado de ánimo depresivo y fatiga. Objetive: Evaluar la disfunción sexual en mujeres con EPOC y posibles mecanismos explicativos de esas dos condiciones Métodos: Participaron 70 pacientes mujeres con EPOC, rango edad 36-65 años y 70 controles emparejados por edad. Todos los sujetos respondieron un cuestionario para el índice funcional sexual femenino e inventario de depresión de BECK, mas una espirometría. Resultados: Se observó disfunción sexual significativa en las pacientes con EPOC comparado con el grupo sin EPOC. Las puntuaciones del inventario de depresión BECK fueron significativamente inferiores a las del grupo control. No hubo correlación entre las puntuaciones del FSFI y la depresión BECK con las características de las "mujeres" (r=-0.055). No se encontraron diferencias significativas en edad, FEV1% y antecedentes de exacerbación del año anterior según la gravedad de la depresión. En la regresión lineal para determinar la depresión, no hubo ningún factor estadísticamente significativo entre edad, número de comorbilidades y FEV1/FVC% predicho. En el multivariado, sólo la fatiga durante el coito resultó ser un factor significativo para predecir la disfunción sexual entre factores como edad, presencia de comorbilidades, duración de la enfermedad, hábito tabáquico, FEV1%, m MRCpoints, prueba de la marcha de 6 minutos y puntuaciones de depresión de BECK. Conclusiones: La disfunción sexual parece no estar relacionada con las medidas espirométricas o la capacidad de ejercicio, pero si con la fatiga. La depresión es una comorbilidad frecuente, de la que a menudo se descuidan ambos trastornos.

El eje cardiopulmonar y la mortalidad cardiovascular en el paciente EPOC / Cardiopulmonary axis and cardiovascular mortality in patients with COPD

La enfermedad pulmonar obstructiva crónica (EPOC) es la cuarta causa de mortalidad en nuestro medio y habitualmente se consideraba circunscrita al territorio pulmonar. Los estudios más novedosos sugieren que se trata de una enfermedad sistémica cuya etiopatogenia más probable es un estado de inflamación crónica de baja intensidad que se reagudiza durante las exacerbaciones. La evidencia científica reciente ha puesto de relieve que las enfermedades cardiovasculares son una de las principales causas de hospitalización y mortalidad en estos pacientes. Esta relación debe comprenderse considerando que ambos sistemas, el pulmonar y el cardiovascular, se encuentran íntimamente relacionados constituyendo el eje cardiopulmonar. Por lo tanto, el abordaje terapéutico de la EPOC no debe comprender solo el tratamiento de las complicaciones respiratorias, sino también la prevención y tratamiento de las enfermedades cardiovasculares, muy frecuentes en estos pacientes. En este sentido, en los últimos años se han desarrollado estudios que analizan el efecto de los diferentes tipos de terapia inhalada sobre la mortalidad por todas las causas y la mortalidad cardiovascular en particular (AU)

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of mortality in our environment and was usually considered to be confined to the lung territory. The latest studies suggest that it is a systemic disease whose most probable etiopathogenesis is a state of low-intensity chronic inflammation that worsens during exacerbations. And recent scientific evidence has highlighted that cardiovascular diseases are one of the main causes of hospitalization and mortality in these patients. This relationship must be understood considering that both systems, the pulmonary and the cardiovascular, are closely related constituting the cardiopulmonary axis. Therefore, the therapeutic approach to COPD should not only include the treatment of respiratory complications, but also the prevention and treatment of cardiovascular diseases, which are very common in these patients. In this sense, in the last years, studies have been carried out that analyze the effect of the different types of inhaled therapy on all-cause mortality and cardiovascular mortality in particular (AU)